All In Biotech

Drug Trial Radar · NCT06149559

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

14

Actual

Start

Jun 14, 2024

Primary completion

Oct 5, 2026

Study completion Oct 5, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • rozanolixizumabDrug

    rozanolixizumab solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) VisitTime frame: From Baseline up to the EOS Visit (up to 18 weeks)
  2. Occurrence of TEAEs leading to permanent withdrawal of Investigational Medicinal Product (IMP) up to the EOS VisitTime frame: From Baseline up to the EOS Visit (up to 18 weeks)
  3. Occurrence of Adverse Event(s) of Special Monitoring (AESM) up to the EOS Visit (up to 18 weeks)Time frame: From Baseline up to the EOS Visit (up to 18 weeks)

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Mg0006 40290

    Bologna, Italy

  • Mg0006 40144

    Milan, Italy

  • Mg0006 40733

    Naples, Italy

  • Mg0006 20340

    Fuchu-shi, Japan

  • Mg0006 20339

    Ōbu, Japan

  • Mg0006 20343

    Sagamihara, Japan

  • Mg0006 40734

    Lodz, Poland

  • Mg0006 40155

    Warsaw, Poland

  • Mg0006 40841

    Yenimahalle, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.